Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KDR Q472H |
| Gene Variant Detail | |
| Relevant Treatment Approaches | VEGFR Inhibitor (Pan) VEGFR2 Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KDR Q472H | melanoma | sensitive | unspecified VEGFR2 antibody | Preclinical | Actionable | In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613). | 26631613 | |
| KDR Q472H | melanoma | sensitive | VEGFR Inhibitor (Pan) | Dabrafenib + Lenvatinib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of Tafinlar (dabrafenib) and Lenvima (lenvatinib) synergistically inhibited viability of melanoma cell lines expressing KDR Q472H compared to cells expressing wild-type KDR in culture (PMID: 38201446). | 38201446 |
| KDR Q472H | melanoma | sensitive | VEGFR Inhibitor (Pan) | Dabrafenib + Lenvatinib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Lenvima (lenvatinib) treatment to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) decreased proliferation compared to the combination alone in melanoma cell lines expressing KDR Q472H in culture (PMID: 38201446). | 38201446 |
| KDR Q472H | epithelioid sarcoma | predicted - sensitive | VEGFR Inhibitor (Pan) | Everolimus + Vandetanib | Case Reports/Case Series | Actionable | In a Phase I trial, treatment with the combination of Afinitor (everolimus) and Caprelsa (vandetanib) was well tolerated and resulted in a median progression-free survival of 3.3 months, median overall survival of 4.6 months, clinical benefit rate of 38% in pediatric and young adult patients with advanced solid tumors, including 1 partial response in a 20 year-old patient with metastatic epithelioid sarcoma harboring germline KDR Q472H (PMID: 37879233; NCT01582191). | 37879233 |